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INTRODUCTION
Using combined chemotherapy, pediatric ALL (acute lympho-
blastic leukemia) is a very curable disease. In Hungary,
approximately 85% of patients with ALL survive 5 years after
therapy [1]. The Berlin–Frankfurt–Mu¨nster (BFM) group first used
the nucleoside analogue cytarabine (cytosine arabinoside, 1-b-D-
arabinofuranosylcytosine, ara-C) in 1981 in combination with
methotrexate, cyclophosphamide and doxorubicin [2–4]. However,
the therapeutic agents used in the treatment of this disease are
highly toxic and induce serious side effects. The major toxicities of
ara-C at standard doses are myelosuppression, mucositis and
infection [5]. Cytopenias as the result of myelosuppression can
rapidly become life threatening or affect the quality of life, often
leading to interruptions in chemotherapy and a subsequent increase
in the risk of relapse. Because there is a high interpatient variability
of sensitivity and toxicity to ara-C, understanding the background
of this variance could provide an opportunity to identify patients at
increased risk of adverse reactions. Genetic variations in the key
genes involved in the transport and metabolism of ara-C may play
an important role in these interpatient differences [6–8].
Ara-C requires active cellular uptake via nucleoside transporters
(Fig. 1). The primary transporters are SLC29A1 (solute carrier family
29 member 1, previous name is equilibrative nucleoside transporter,
hENT1) which transports 80% of the drug, and SLC28A1 (solute
carrier family 28 member 1, previous name is human concentrative
nucleoside transporter, hCNT1) [8–11]. The expression of SLC28A3
(solute carrier family 28 member 3, previous name is human
concentrative nucleoside transporter, hCNT3) was slightly increased
in H9-ara-C cells selected with high-dose ara-C [11]. Inside the cell,
ara-C is metabolized by the same pathway as other nucleoside
analogs; e.g., gemcitabine, decitabine, and clofarabine [9]. Conver-
sion of ara-C into cytosine arabinoside-monophosphate (ara-CMP)
by deoxycytidine kinase (DCK) is the rate-limiting step for further
phosphorylation [6,7]. Cytidine monophosphate kinase 1 (CMPK1)
converts ara-CMP into cytosine arabinoside-diphosphate (ara-CDP).
Several nucleoside diphosphate kinases (NDPs) take part in the
conversion of ara-CDP to cytosine arabinoside-triphosphate (ara-
CTP) [9,12]. The intracellular conversion of ara-C into the active
derivate ara-CTP is indispensable to exert its cytotoxic effect, which
occurs in the S-phase of the cell cycle. Ara-CTP is incorporated
into the DNA, competitively inhibiting DNA synthesis and DNA-
polymerase-a [9,12–14]. Ara-C and ara-CMP are degraded by
cytidine deaminase (CDA) and deoxycytidine-monophosphate
deaminase (DCTD) into the non-toxic metabolite 1-B-D-arabinofur-
anosyl-uracil (ara-U) and arabinofuranosyl-uracil-monophosphate
(ara-UMP), respectively [14,15]. Ara-CMP is dephosphorylated
by 50 nucleotidase II (NT5C2), thereby preventing the
production of ara-CTP [14,16]. Several feedback mechanisms
influence the metabolism of ara-C, For example, deoxycytidine
triphosphate (dCTP) is a potent feedback inhibitor of DCK [17].
Intracellular dCTP pools are regulated by ribonucleotide
reductase holoenzyme (consisting of RRM1 and RRM2 subunits)
(Fig. 1) [18].
Background. Cytarabine (cytosine arabinoside, ara-C) is a
chemotherapeutical agent used in the treatment of pediatric acute
lymphoblastic leukemia (ALL). Adverse drug reactions, such as
interpatient variability in sensitivity to ara-C, are considerable and
may cause difficulties during chemotherapy. Single nucleotide
polymorphisms (SNPs) can play a significant role in modifying
nucleoside-drug pharmacokinetics and pharmacodynamics and thus
the development of adverse effects. Our aim was to determine
whether polymorphisms in genes encoding transporters and enzymes
responsible for the metabolism of ara-C are associated with toxicity
and clinical outcome in a patient population with childhood ALL.
Procedure. We studied 8 SNPs in the CDA,DCK, DCTD, SLC28A3,
and SLC29A1 genes in 144 patients with childhood acute
lymphoblastic leukemia treated according to ALLIC BFM 1990,
1995 and 2002 protocols. Results. DCK rs12648166 and DCK
rs4694362 SNPs were associated with hematologic toxicity (OR ¼
2.63, CI 95% ¼ 1.37–5.04, P¼0.0036 and OR ¼ 2.53, CI 95% ¼
1.34–4.80, P¼0.0044, respectively). Conclusions. Our results
indicate that DCK polymorphisms might be important genetic risk
factors for hematologic toxicity during ALL treatment with ara-C.
Individualized chemotherapy based on genetic profiling may help to
optimize ara-C dosing, leading to improvements in clinical outcome
and reduced toxicity. Pediatr Blood Cancer 2014;9999:1–7
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Several in vitro studies have verified that the intracellular level
of ara-CTP is determined by cellular sensitivity to ara-C [6,7].
In vivo observations have revealed an association between complete
remission and intracellular levels of ara-C [16]. In recent years,
numerous SNPs (single nucleotide polymorphisms) in genes of the
ara-C metabolic pathway were identified as factors modifying
nucleoside-drug pharmacokinetics and pharmacodynamics [19].
These genetic alterations might have clinical consequences
[20–22].
Our aim was to test the hypothesis that genetic polymorphisms
in ara-C transport and metabolism affect the hematologic toxicity
and outcome of patients with childhood ALL treated with ara-C.
Eight SNPs of the candidate genes CDA, DCK, DCTD, SLC28A3
and SLC29A1 were studied. These genes could form the molecular
basis of the interpatient variability observed in intracellular ara-
CTP concentration, toxicity to ara-C and survival after leukemia.
METHODS
Patients
In this retrospective study, 144 patients with childhood acute
lymphoblastic leukemia diagnosed between 1991 and 2007 were
enrolled. A detailed description of the study population may be
found in Table I. The patients received chemotherapy following
the ALL BFM 1990, 1995 or ALL IC BFM 2002 protocols at two
Hungarian children oncology centers: the 2nd Department of
Pediatrics, Semmelweis University, Budapest, and the Department
of Pediatrics, Faculty of Medicine, University of Szeged. Following
the protocol, cases were classified into three risk-groups based on
initial clinical, pathological and genetic characteristics and
response to early therapy as low risk (LR), medium risk (MR)
and high risk (HR). Children with co-morbidities that may affect
clinical outcome and toxicity were excluded from this study. We
followed the patients for at least 5 years or until the date of death.
All study subjects belonged to the Hungarian population. Written
informed consent was requested from the guardians of the patients
prior to their inclusion in the study. The study was approved by the
Ethics Committee of the Hungarian Medical Research Council and
conducted according to the principles of the Declaration of
Helsinki.
The chemotherapy regimen is described in detail in our previous
article [23]. In brief, ara-C was administered in the intensification and
reintensification phases. We investigated ara-C toxicity during the
intensification phase only. In every protocol and risk group, the
patients were treated 8–16 times with 75 mg/m2 doses of ara-C
intravenously. The course of the dosing was daily doses of 75 mg/m2
for 4 days repeated for 2 or 4 weeks according to the ALL BFM 1990/
1995 and ALL IC BFM 2002 protocols. During the therapy, patients
received 60 mg/m2 6-mercaptopurine (6-MP) orally daily; and one or
two doses of methotrexate intrathecally. Two days before the first ara-
C administration, the patients were given a single dose of intravenous
cyclophosphamide (1 g/m2). Leukopenia, thrombocytopenia, ane-
mia, nephrotoxicity (characterized by creatinine levels), hepatotox-
icity (determined from glutamate pyruvate transaminase, [GPT]
activity), encephalopathy (defined as any neurological symptoms)
and infections (characterized by antibiotic usage and fever grade 2–4)
were monitored in the patients’ medical records. These adverse drug
reactions were graded according to Common Terminology Criteria
for Adverse Events v3.0 (CTCAE). Detailed description of the
toxicities are in Table I. Toxicity data during the weeks of the ara-C
containing cycles plus the following two-week-long break before
commencing the next therapeutic regimen were collected. The 5-year
event-free survival (EFS) was calculated from the date of diagnosis to
the date of relapse.
SNP Selection, DNA Extraction and Genotyping
We selected 8 SNPs in the CDA, DCK, DCTD, SLC28A3, and
SLC29A1 genes according to the following criteria: (i) the minor
allele frequency of the SNP is greater than 10% among Caucasians;
(ii) synonymous or intronic SNPs; and (iii) SNPs that have been
associated with cancer risk or clinical outcome in previous
investigations. The genes, nucleotide substitutions, function (such
as encoding amino acid changes), and reference SNP identification
numbers of the 8 SNPs evaluated in this study are summarized in
Table II. DNA was isolated from peripheral blood taken during
remission using Qiagen isolation kits (QIAmp DNA Blood Maxi
Kit, Qiagen, Hilden, Germany).
The SNPs were genotyped using the fluorescence-based
competitive allele-specific KASPTM by Design genotyping assays
(LGC Genomics, Teddington, UK) according to the manufacturer’s
instructions. PCR reactions were carried out using a 7900HT Fast
Fig. 1. Schematic description of ara-C transport and metabolism. Bold
letters indicate the genes investigated in this study. Abbreviations:
Ara-C cytosine arabinoside; ara-CMP cytosine arabinoside-
monophosphate; ara-CDP cytosine arabinoside-diphosphate;
ara-CTP cytosine arabinoside-triphosphate; ara-U arabinofuranosyl-
uracil; ara-UMP arabinofuranosyl-uracil-monophosphate; CDA cyti-
dine deaminase; DCK deoxycytidine kinase; CMPK1 cytidine
monophosphate kinase 1; DCTD deoxycytidylate deaminase; dCDP
deoxycytidine diphosphate; dCTP deoxycytidine triphosphate; NDPs
nucleoside diphosphate kinases; NT5C2 50nucleotidase; RRM1, RRM2
ribonucleotide reductase M 1,2; SLC28A1, SLC28A3 solute carrier
family 28 member 1, 3; SLC29A1 solute carrier family 29 member 1.
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Real-Time PCR System (Life Technologies, Grand Island, NY).
Samples with known genotypes were used in every measurement
for technical control.
Statistical Methods
A Hardy–Weinberg equilibrium (HWE) analysis for genotype
distribution and differences in allele distribution between the groups
was carried out using a x2 goodness-of-fit test using an online
application (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). A significant
violation of HWE was considered when P< 0.05. Unadjusted
logistic regression and multi-adjusted logistic regression models
were applied to obtain odds ratios (OR) and 95% confidence intervals
(95% CI) to estimate the risk for each polymorphism to toxicity. To
assess the effect of the genetic background on blood counts, multi-
adjusted general linear model procedures were used. Gender (male–
female) and age (years) at diagnosis were used as potential cofactors.
Three genotype groups were analyzed separately when the number of
patients was sufficient in each group (n> 5). A Bonferroni correction
considering multiple testing for the 8 SNPs was performed
(P< 0.00625 was considered as significant).
Linkage disequilibrium (indicated with D’ and r2) and estimated
haplotype frequencies in cases and controls were calculated using
Haploview 4.1 software (http://www.broad.mit.edu/mpg/haplo-
view/). Haplotype blocks were generated for all genes with at
least two SNPs (DCK, SLC28A3, SLC29A1). The haplotype-
specific odds ratio (OR) was estimated using logistic regression.
The survival rates were estimated with the Kaplan–Meier method.
Statistical analysis was performed using IBM SPSS Statistics 21
(IBM Corporation, Armonk, NY) and MedCalc 10.0.2.0 (MedCalc
Software, Ostend, Belgium) software.
TABLE I. Characteristics of Patients
Variable Data
Gender (%) Male (%) 65 (45)
Female (%) 79 (55)
Age at diagnosis Mean ( SD) 6.7 ( 8.1)
Median (range) 2 (0.5–17.5)
Risk (%) LR (%) 36 (25)
MR (%) 97 (67)
HR (%) 11 (8)
White blood cells (10  9/L) Median (range) 1.3 (0.2–4.3)
Leukopenia (%) Grade 1–2 (>2.0  10  9/L) 31 (22)
Grade 3–4 (<2.0  10  9/L) 109 (78)
Trombocytes (10  9/L) Median (range) 77 (5–416)
Thrombopenia (%) Grade 1–2 (>50  10  9/L) 103 (73)
Grade 3–4 (<50  10  9/L) 38 (27)
Hemoglobin (g/l) Median (range) 75 (40–125)
Anemia (%) Grade 1–2 (>80  10  9/L) 53 (36)
Grade 3–4 (<80  10  9/L) 91 (64)
Antibiotics usage (%) No 99 (69)
Yes 45 (31)
Fever (%) No 89 (62)
Grade 2–4 (39.0˚C) 55 (38)
Survival OS (5 year) 87.1%
EFS (5 year) 83.5%
LR, low risk; MR, medium risk; HR, high risk; OS, overall; EFS, event free survival.
TABLE II. The Studied SNPs, Distribution of Genotypes and Alleles in ALL Children
Genotype (%)
Gene Rs number Chr. Function Minor allele (MAF) 11 12 22
CDA rs1048977 1p36.2 Thr145Thr T (0.31) 70 (50) 51 (37) 18 (13)
DCK rs12648166 4q13.3 intron A (0.40) 48 (36) 67 (50) 20 (15)
rs4694362 intron C (0.40) 49 (36) 66 (49) 21 (15)
DCDT rs4742 4q35.1 Val116Val C (0.30) 69 (51) 52 (38) 15 (11)
SLC28A3 rs7867504 9q21.3 Thr89Thr C (0.31) 60 (45) 64 (48) 9 (7)
rs7853758 Leu461Leu A (0.13) 102 (77) 28 (21) 3 (2)
SLC29A1 rs324148 6p21.1 intron T (0.21) 83 (61) 48 (35) 5 (4)
rs9394992 intron T (0.30) 68 (49) 59 (42) 13 (9)
Chr, chromosome; MAF, minor allele frequency; SNP, single nucleotide polymorphism; The genotype groups are indicated by: 11¼ homozygote
for the frequent allele; 12 ¼ heterozygote; 22 ¼ homozygote for the rare allele.
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RESULTS
Genotype and Allele Frequencies
The 8 SNPs were genotyped in the patient population; the minor
allele and genotype frequencies are presented in Table II. The
genotype distributions were in Hardy–Weinberg equilibrium for all
SNPs.
Association Between SNPs and Toxicity
Leukopenia, thrombocytopenia, anemia, nephrotoxicity,
hepatotoxicity, encephalopathy and infections were monitored
in our childhood acute lymphoblastic leukemia patient cohort.
None of the patients had nephrotoxicity. Hepatotoxicity was
detected in three patients, but with certainly due to other causes,
such as hepatotropic virus infection. They were excluded from
our patient cohort. One patient had encephalopathy after
exposure to ara-C. Because of these small numbers, it was
not possible to analyze these toxicities in relation to the
genotypes. Leukopenia, thrombocytopenia, anemia and infec-
tions were studied in association with the allele and genotype
frequencies of the polymorphisms. The alleles of two SNPs in
the DCK gene were associated with leukopenia. Patients
carrying the rs12648166 G and rs4694362 T alleles had a
higher risk of grade 3/4 leukopenia (OR¼ 2.25, 95% CI¼ 1.27–
3.99, P¼ 0.005; and OR¼ 2.24, 95% CI¼ 1.26–3.97,
P¼ 0.0053, respectively).
After the analysis of genotype distribution, two SNPs associated
with severe leukopenia were identified in the univariate and in
multi-adjusted models (Table III). More patients had leukopenia
with the DCK rs12648166 GG genotype (41%) compared to
patients with the AA genotype (12%) (OR¼ 2.63, 95% CI¼
1.37–5.04, P¼ 0.0036). Patients with the DCK rs4694362 TT
genotype were more susceptible to leukopenia compared to patients
with the CC genotype (42 vs. 12%) (OR¼ 2.53, 95% CI¼
1.34–4.80, P¼ 0.0044).
No association of leukopenia with the other polymorphisms was
observed, neither significant association was found with thrombo-
cytopenia in the investigated population (Table III). Anemia,
infections, total number of white blood cells, total number of
thrombocytes and hemoglobin counts were also studied in relation
to polymorphism, but no associations were observed.
Haplotype Association With Toxicity
Haplotype analyses were carried out to determine the associa-
tion of haplotype blocks of the genes and ara-C side effects, such as
leukopenia and thrombocytopenia. The estimated haplotype
frequencies are shown in Table IV for patients with or without
these side effects. There were significant differences in the
frequencies of the haplotypes of the DCK gene. The GT haplotype
was more frequent in patients with grade 3/4 leukopenia than
among other haplotypes (65% vs. 43%; OR¼ 2.37, 95% CI¼
1.34–4.21, P¼ 0.0031), while the AC haplotypes were less frequent
in patients with grade 3/4 leukopenia than other haplotypes (35%
vs. 57%; OR¼ 0.41, 95% CI¼ 0.23–0.73, P¼ 0.0025). Adverse
effects did not differ among haplotype blocks of the other genes.
The linkage disequilibrium coefficients (D’ and r2) between the
alleles were also calculated (Fig. 2). A strong linkage was found
between the two SNPs (rs12648166 and rs4694362) of the DCK T
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gene (D0 ¼ 1, r2¼ 0.98), but only a slight or no linkage could be
detected between the SNPs of SLC28A3 (D0 ¼ 0.83, r2¼ 0.23) and
SLC29A1 (D0 ¼ 0.17, r2¼ 0.01), respectively.
Survival and Genotype Association With Survival
Overall (OS) and event-free survivals (EFS) were studied in our
population, and the relationship of the genotypes with the overall
and event-free survival rate of our population was determined. The
5-year OS was 87.1% and the 5-year EFS was 83.5%, which are
comparable to the Hungarian survival rate [1]. The SNPs seemed to
have no significant influence on the survival of our pediatric ALL
population.
DISCUSSION
Treatment of patients with acute lymphoblastic leukemia is very
effective, but has serious side effects. In this study, we investigated 8
polymorphisms in 5 genes responsible for the transport and
metabolism of cytosine arabinoside in relationship with ara-C side
effects, leukopenia, thrombocytopenia, anemia and infections. Two
SNPs of the DCK gene, rs12648166 and rs4694362, were
associated with altered risk to leukopenia at the allele, genotype
and haplotype levels. None of the SNPs influenced thrombocyto-
penia, anemia, infection or the survival of the patients.
The relatively small sample size is a limitation of this study. It is
not possible to detect minor associations; also the detected
associations on small cohort would result in difficulty in
interpretating the results. The identified associations must be
replicated in independent patient cohorts and will need validation
on larger populations. Also, it has to be mentioned that patients who
died before the period of sample collection are underrepresented in
our cohort. Apart from this, sample selection was random.
DCK (deoxycytidine kinase) is required for the pharmacologic
activity of several clinically important anticancer nucleoside
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Fig. 2. Linkage disequilibrium analysis of the SNPs. Pairwise linkage
disequilibrium is expressed as r2 and D0 (both from 0 to 1). The value of
r2 is indicated by the shade of the boxes, where the denser shade
represents a higher linkage (r2¼ 0 is white, 0< r2>1 are shades of grey
and r2¼ 1 is black). D0x 100 is indicated in the boxes as numbers when
D’<1.
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analogs. It plays a key role as the first enzyme in the activation of
ara-C to the active metabolite ara-CTP with phosphorylation
because it catalyzes the conversion of ara-C to ara-CMP [24]. Its
activity is also a major determinant of ara-C resistance because the
expression of the DCK gene in ara-C resistant cells was reduced
60% compared to the level in human lymphoid cells. The reduced
mRNA level was correlated with a lower DCK protein level
and reduced protein activity (31.4%). As a consequence, resistant
cells accumulated <1% ara-CTP [7,11]. Several other studies have
investigated the potential function of SNPs of the DCK gene.
Sequencing the promoter region and exons of DCK in
lymphoblastoid cell lines from European origin, Lamba et al.
identified several polymorphisms, such as I24V (rs66878317),
A119G (rs66472932), and P122S (rs67437265), with different
enzymatic activity than the wild-type protein. In addition, one SNP
(35708 C<T rs4643786) in the 30 UTR region was associated with
lower DCK mRNA expression in the cell lines. They also
investigated the potential effect of DCK SNPs on the level of the
active metabolite ara-CTP in patients with acute myeloid leukemia
(AML) who were treated with ara-C. They found that rs4643786
was associated with significantly lower intracellular ara-CTP
concentrations [7].
To identify genetic determinants that contribute to ara-C
toxicity, Hartford et al. conducted a study in which they examined
SNPs in the DCK gene and applied a whole-genome pharmaco-
genomic analysis on lymphoblastoid cell lines (LCLs) derived from
different populations (African or European) [6]. There was strong
correlation between DCK mRNA and protein expression, and a
higher DCK mRNA level was significantly correlated with
cytotoxicity and sensitivity to ara-C. Studying the contribution of
SNPs in the DCK gene to sensitivity to ara-C, they found that
lymphoblastoid cell lines heterozygous for SNP 70 (I24V,
rs66878317) were more sensitive to ara-C and contained more
ara-CTP compared to the homozygous cell lines [6]. These data
provide evidence that genetic variation within the DCK gene can
affect function of the protein.
Several studies investigated the influence of the genetic
background of the patients on treatment response, side effects
and patient survival [25,26], but only a few studies have focused on
the DCK SNPs examined in our study (rs12648166 and rs4694362).
One of those studies analyzed genetic variation in gemcitabine
metabolic and transporter genes that were associated with toxicity
and efficacy of gemcitabine-based therapy in patients with locally
advanced pancreatic cancer [27]. Gemcitabine is a nucleoside
analog with a very similar metabolic pathway to that of cytarabine
(https://www.pharmgkb.org/pathway/PA2036#PGG) [28]. DCK
rs4694362 was associated with neutropenia, and patients with the
TT genotype had a higher risk for having grade 3–4 neutrope-
nia [27]. They also investigated DCK rs12648166, but found no
association. Another study analyzed patients with pancreatic cancer
treated with gemcitabine, and an association was found between
genotype and tumor response to preoperative treatment for both of
the SNPs (rs12648166 and rs4694362), but only patients with the
rs4694362T allele had a higher risk for neutropenia [29]. The SNP
rs4694362 of the DCK gene was a significant prognostic factor for
overall survival in patients with AML from Korea; having at least
one T allele was significantly associated with better survival time
compared to the CC genotype [30].
Nevertheless, some studies detected associations between DCK
function or ara-C toxicity and SNPs near DCK rs4694362, which
were associated with ara-C toxicity in our population. One of these
is rs4643786 in the 30 UTR of DCK found by Lamba et al. [7], which
might be in linkage disequilibrium with rs4694362, because the two
SNPs are very close to each other (approximately 1400 bp). The
rs72552079 in the 30 UTR region of the DCK which is
approximately 1800 bp from rs4694362, seems to influence the
outcome of the therapy because carrying at least one T allele in
rs72552079 is associated with a better response to the therapy [31].
Polymorphisms in the 50 regulatory region of DCK also might
have biological and clinical effects. For example, Chinese patients
with a -360CC/-201CC genotype had less DCK mRNA, lower
transcriptional activation activity and a poor response to
chemotherapy [32].
Genome-wide association (GWA) studies investigating the
genetics of chemotherapeutic susceptibility of ara-C in lympho-
blastoid cell lines have not identified the ara-C metabolizing
enzymes (SLC29A1, DCK, CDA) [33–36]. This result could
attributed to the genes described above that may be more
responsible for the side effects of the treatment.
Personalized dosing of chemotherapeutic agents based on the
patient’s genetic background can decrease life-threatening tox-
icities and side effects [37]. Our results may contribute to a better
understanding of the pharmacogenetic background of cytarabine
toxicity in patients with childhood acute lymphoblastic leukemia.
Better elucidation of the pharmacogenetics of interindividual
differences could help to individualize chemotherapy and thus
potentially improve outcome.
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